The estrogen receptors ERα and ERβ are directly involved in carcinogenesis and tumor progression in multiple neoplasms of the female genital tract, and ERα was the first molecule amenable to drug targeting in BC, where its presence in cancer cells is still one of the main markers for identification of patients that will benefit from endocrine therapy. This evidence concerns the gene ESR2 and cancer.